GALT
Galectin Therapeutics Inc.
Biotechnology
Market Cap$136M
5Y Perf.-23.3%
Compare Stocks
4 / 10Try these comparisons:
Stock Comparison
GALT vs ELVN vs IMVT vs NUVL
Revenue, margins, valuation, and 5-year total return — side by side.
ELVN
Enliven Therapeutics, Inc.
Biotechnology
Market Cap$2.39B
5Y Perf.+86.9%
IMVT
Immunovant, Inc.
Biotechnology
Market Cap$5.53B
5Y Perf.+160.2%
NUVL
Nuvalent, Inc.
Biotechnology
Market Cap$7.53B
5Y Perf.+461.1%
GALT vs ELVN vs IMVT vs NUVL — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | GALT | ELVN | IMVT | NUVL |
|---|---|---|---|---|
| Industry | Biotechnology | Biotechnology | Biotechnology | Biotechnology |
| Market Cap | $136M | $2.39B | $5.53B | $7.53B |
| Revenue (TTM) | $0.00 | $0.00 | $0.00 | $0.00 |
| Net Income (TTM) | $-37M | $-104M | $-464M | $-450M |
| Total Debt | $106M | $0.00 | $98K | $0.00 |
| Cash & Equiv. | $15M | $99M | $714M | $262M |
GALT vs ELVN vs IMVT vs NUVL — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
GALT
ELVN
IMVT
NUVL
| Stock | Jul 21 | May 26 | Return |
|---|---|---|---|
| Galectin Therapeuti… (GALT) | 100 | 76.7 | -23.3% |
| Enliven Therapeutic… (ELVN) | 100 | 186.9 | +86.9% |
| Immunovant, Inc. (IMVT) | 100 | 260.2 | +160.2% |
| Nuvalent, Inc. (NUVL) | 100 | 561.1 | +461.1% |
Price return only. Dividends and distributions are not included.
Quick Verdict: GALT vs ELVN vs IMVT vs NUVL
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: ELVN leads in 3 of 6 categories, making it the strongest pick for profitability and margin quality and recent price momentum and sentiment. Galectin Therapeutics Inc. is the stronger pick specifically for capital preservation and lower volatility and dividend income and shareholder returns. NUVL also leads in specific categories worth noting. As sector peers, any of these can serve as alternatives in the same allocation.
GALT
Galectin Therapeutics Inc.
The Income Pick
GALT is the #2 pick in this set and the best alternative if income & stability and sleep-well-at-night is your priority.
- Dividend streak 0 yrs, beta 0.70, yield 0.1%
- Lower volatility, beta 0.70, current ratio 0.49x
- Beta 0.70 vs IMVT's 1.37
- 0.1% yield; the other 3 pay no meaningful dividend
Best for: income & stability and sleep-well-at-night
ELVN
Enliven Therapeutics, Inc.
The Growth Play
ELVN carries the broadest edge in this set and is the clearest fit for growth exposure.
- EPS growth 3.2%
- 3.4% margin vs GALT's -29.7%
- +120.5% vs GALT's +34.4%
- -23.4% ROA vs GALT's -290.0%
Best for: growth exposure
IMVT
Immunovant, Inc.
The Secondary Option
IMVT lags the leaders in this set but could rank higher in a more targeted comparison.
Best for: healthcare exposure
NUVL
Nuvalent, Inc.
The Long-Run Compounder
NUVL is the clearest fit if your priority is long-term compounding and defensive.
- 446.1% 10Y total return vs IMVT's 173.6%
- Beta 1.09, current ratio 15.27x
- 1.1% revenue growth vs GALT's -59.9%
Best for: long-term compounding and defensive
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | NUVL | 1.1% revenue growth vs GALT's -59.9% |
| Quality / Margins | ELVN | 3.4% margin vs GALT's -29.7% |
| Stability / Safety | GALT | Beta 0.70 vs IMVT's 1.37 |
| Dividends | GALT | 0.1% yield; the other 3 pay no meaningful dividend |
| Momentum (1Y) | ELVN | +120.5% vs GALT's +34.4% |
| Efficiency (ROA) | ELVN | -23.4% ROA vs GALT's -290.0% |
GALT vs ELVN vs IMVT vs NUVL — Financial Metrics
Side-by-side numbers across 4 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLELVNLAGGINGIMVT
Who Leads Where
ELVN leads in 2 of 6 categories
GALT leads 1 • NUVL leads 1 • IMVT leads 0 • 1 tied
Explore the data ↓IMVTImmunovant, Inc.
0leads
NUVLNuvalent, Inc.
1leads
GALTGalectin Therapeutics…
1leads
ELVNEnliven Therapeutics,…
2leads
6 Total Categories
CATEGORYLEADERvs GALTvs NUVLMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
GALT1/1
Valuation MetricsMultiples, price ratios, and targets
ELVN2/2
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
ELVN5/8
Total Returns1Y, 3Y, 5Y total returns with dividends
NUVL4/6
Risk & VolatilityBeta, volatility, and downside exposure
Tied
—
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
GALT leads this category, winning 1 of 1 comparable metric.
Income & Cash Flow (Last 12 Months)
GALT and NUVL operate at a comparable scale, with $0 and $0 in trailing revenue.
| Metric | GALTGalectin Therapeu… | ELVNEnliven Therapeut… | IMVTImmunovant, Inc. | NUVLNuvalent, Inc. |
|---|---|---|---|---|
| RevenueTrailing 12 months | $0 | $0 | $0 | $0 |
| EBITDAEarnings before interest/tax | -$31M | -$119M | -$487M | -$346M |
| Net IncomeAfter-tax profit | -$37M | -$104M | -$464M | -$450M |
| Free Cash FlowCash after capex | -$31M | -$70M | -$423M | -$313M |
| Gross MarginGross profit ÷ Revenue | — | — | — | — |
| Operating MarginEBIT ÷ Revenue | — | — | — | — |
| Net MarginNet income ÷ Revenue | — | — | — | — |
| FCF MarginFCF ÷ Revenue | — | — | — | — |
| Rev. Growth (YoY)Latest quarter vs prior year | — | — | — | — |
| EPS Growth (YoY)Latest quarter vs prior year | +27.8% | +2.2% | +19.7% | -17.8% |
GALT leads this category, winning 1 of 1 comparable metric.
Valuation Metrics
ELVN leads this category, winning 2 of 2 comparable metrics.
Valuation Metrics
| Metric | GALTGalectin Therapeu… | ELVNEnliven Therapeut… | IMVTImmunovant, Inc. | NUVLNuvalent, Inc. |
|---|---|---|---|---|
| Market CapShares × price | $136M | $2.4B | $5.5B | $7.5B |
| Enterprise ValueMkt cap + debt − cash | $227M | $2.3B | $4.8B | $7.3B |
| Trailing P/EPrice ÷ TTM EPS | -2.78x | -22.02x | -9.97x | -17.50x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | — | — | — |
| EV / EBITDAEnterprise value multiple | — | — | — | — |
| Price / SalesMarket cap ÷ Revenue | — | — | — | — |
| Price / BookPrice ÷ Book value/share | — | 4.97x | 5.83x | 5.96x |
| Price / FCFMarket cap ÷ FCF | — | — | — | — |
ELVN leads this category, winning 2 of 2 comparable metrics.
Profitability & Efficiency
ELVN leads this category, winning 5 of 8 comparable metrics.
Profitability & Efficiency
ELVN delivers a -24.2% return on equity — every $100 of shareholder capital generates $-24 in annual profit, vs $-47 for IMVT. On the Piotroski fundamental quality scale (0–9), ELVN scores 3/9 vs NUVL's 1/9, reflecting mixed financial health.
| Metric | GALTGalectin Therapeu… | ELVNEnliven Therapeut… | IMVTImmunovant, Inc. | NUVLNuvalent, Inc. |
|---|---|---|---|---|
| ROE (TTM)Return on equity | — | -24.2% | -47.1% | -42.8% |
| ROA (TTM)Return on assets | -2.9% | -23.4% | -44.1% | -37.8% |
| ROICReturn on invested capital | — | -32.8% | — | -32.5% |
| ROCEReturn on capital employed | — | -31.1% | -66.1% | -34.4% |
| Piotroski ScoreFundamental quality 0–9 | 1 | 3 | 2 | 1 |
| Debt / EquityFinancial leverage | — | — | 0.00x | — |
| Net DebtTotal debt minus cash | $91M | -$99M | -$714M | -$262M |
| Cash & Equiv.Liquid assets | $15M | $99M | $714M | $262M |
| Total DebtShort + long-term debt | $106M | $0 | $98,000 | $0 |
| Interest CoverageEBIT ÷ Interest expense | -4.24x | — | — | -26.85x |
ELVN leads this category, winning 5 of 8 comparable metrics.
Total Returns (Dividends Reinvested)
NUVL leads this category, winning 4 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in NUVL five years ago would be worth $54,613 today (with dividends reinvested), compared to $5,275 for GALT. Over the past 12 months, ELVN leads with a +120.5% total return vs GALT's +34.4%. The 3-year compound annual growth rate (CAGR) favors NUVL at 39.5% vs GALT's 3.9% — a key indicator of consistent wealth creation.
| Metric | GALTGalectin Therapeu… | ELVNEnliven Therapeut… | IMVTImmunovant, Inc. | NUVLNuvalent, Inc. |
|---|---|---|---|---|
| YTD ReturnYear-to-date | -47.9% | +159.3% | +5.1% | +1.5% |
| 1-Year ReturnPast 12 months | +34.4% | +120.5% | +96.1% | +53.5% |
| 3-Year ReturnCumulative with dividends | +12.2% | +110.5% | +40.9% | +171.2% |
| 5-Year ReturnCumulative with dividends | -47.2% | +38.9% | +62.4% | +446.1% |
| 10-Year ReturnCumulative with dividends | +67.4% | -32.9% | +173.6% | +446.1% |
| CAGR (3Y)Annualised 3-year return | +3.9% | +28.2% | +12.1% | +39.5% |
NUVL leads this category, winning 4 of 6 comparable metrics.
Risk & Volatility
Evenly matched — GALT and NUVL each lead in 1 of 2 comparable metrics.
Risk & Volatility
GALT is the less volatile stock with a 0.70 beta — it tends to amplify market swings less than IMVT's 1.37 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. NUVL currently trades 90.6% from its 52-week high vs GALT's 29.6% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | GALTGalectin Therapeu… | ELVNEnliven Therapeut… | IMVTImmunovant, Inc. | NUVLNuvalent, Inc. |
|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 0.70x | 1.27x | 1.37x | 1.09x |
| 52-Week HighHighest price in past year | $7.13 | $48.50 | $30.09 | $113.02 |
| 52-Week LowLowest price in past year | $1.21 | $14.79 | $13.36 | $63.56 |
| % of 52W HighCurrent price vs 52-week peak | +29.6% | +83.1% | +90.5% | +90.6% |
| RSI (14)Momentum oscillator 0–100 | 41.9 | 49.7 | 60.2 | 52.9 |
| Avg Volume (50D)Average daily shares traded | 347K | 1.1M | 1.4M | 544K |
Evenly matched — GALT and NUVL each lead in 1 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Analyst consensus: GALT as "Buy", ELVN as "Buy", IMVT as "Buy", NUVL as "Buy". Consensus price targets imply 421.3% upside for GALT (target: $11) vs 7.5% for ELVN (target: $43).
| Metric | GALTGalectin Therapeu… | ELVNEnliven Therapeut… | IMVTImmunovant, Inc. | NUVLNuvalent, Inc. |
|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy | Buy | Buy |
| Price TargetConsensus 12-month target | $11.00 | $43.33 | $45.50 | $144.40 |
| # AnalystsCovering analysts | 11 | 6 | 23 | 14 |
| Dividend YieldAnnual dividend ÷ price | +0.1% | — | — | — |
| Dividend StreakConsecutive years of raises | 0 | — | — | — |
| Dividend / ShareAnnual DPS | $0.00 | — | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | +0.0% | 0.0% | 0.0% |
Insufficient data to determine a leader in this category.
Key Takeaway
ELVN leads in 2 of 6 categories (Valuation Metrics, Profitability & Efficiency). GALT leads in 1 (Income & Cash Flow). 1 tied.
Best OverallEnliven Therapeutics, Inc. (ELVN)Leads 2 of 6 categories
Loading custom metrics...
GALT vs ELVN vs IMVT vs NUVL: Key Questions Answered
8 questions · data-driven answers · updated daily
01Is GALT or ELVN or IMVT or NUVL a better buy right now?
Analysts rate Galectin Therapeutics Inc.
(GALT) a "Buy" — based on 11 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — GALT or ELVN or IMVT or NUVL?
Over the past 5 years, Nuvalent, Inc.
(NUVL) delivered a total return of +446. 1%, compared to -47. 2% for Galectin Therapeutics Inc. (GALT). Over 10 years, the gap is even starker: NUVL returned +446. 1% versus ELVN's -32. 9%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — GALT or ELVN or IMVT or NUVL?
By beta (market sensitivity over 5 years), Galectin Therapeutics Inc.
(GALT) is the lower-risk stock at 0. 70β versus Immunovant, Inc. 's 1. 37β — meaning IMVT is approximately 96% more volatile than GALT relative to the S&P 500.
04Which is growing faster — GALT or ELVN or IMVT or NUVL?
On earnings-per-share growth, the picture is similar: Enliven Therapeutics, Inc.
grew EPS 3. 2% year-over-year, compared to -48. 9% for Nuvalent, Inc.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — GALT or ELVN or IMVT or NUVL?
Galectin Therapeutics Inc.
(GALT) is the more profitable company, earning 0. 0% net margin versus 0. 0% for Nuvalent, Inc. — meaning it keeps 0. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: GALT leads at 0. 0% versus 0. 0% for NUVL. At the gross margin level — before operating expenses — GALT leads at 0. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Which pays a better dividend — GALT or ELVN or IMVT or NUVL?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
07Is GALT or ELVN or IMVT or NUVL better for a retirement portfolio?
For long-horizon retirement investors, Galectin Therapeutics Inc.
(GALT) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 70)). Both have compounded well over 10 years (GALT: +67. 4%, ELVN: -32. 9%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
08What are the main differences between GALT and ELVN and IMVT and NUVL?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.